T. Vassilakopoulos Et Al. , "REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS," 17th International Conference on Malignant Lymphoma , Switzerland, pp.410-411, 2023
Vassilakopoulos, T. Et Al. 2023. REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS. 17th International Conference on Malignant Lymphoma , (Switzerland), 410-411.
Vassilakopoulos, T., FERHANOĞLU, A. B., Horowitz, N. A., Mellios, Z., KAYNAR, L., Zektser, M., ... Symeonidis, A.(2023). REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS . 17th International Conference on Malignant Lymphoma (pp.410-411). , Switzerland
Vassilakopoulos, Theodoros Et Al. "REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS," 17th International Conference on Malignant Lymphoma, Switzerland, 2023
Vassilakopoulos, Theodoros Et Al. "REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS." 17th International Conference on Malignant Lymphoma , Switzerland, pp.410-411, 2023
Vassilakopoulos, T. Et Al. (2023) . "REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS." 17th International Conference on Malignant Lymphoma , Switzerland, pp.410-411.
@conferencepaper{conferencepaper, author={Theodoros Vassilakopoulos Et Al. }, title={REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS}, congress name={17th International Conference on Malignant Lymphoma}, city={}, country={Switzerland}, year={2023}, pages={410-411} }